95 related articles for article (PubMed ID: 36608816)
21. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
Patorno E; Najafzadeh M; Pawar A; Franklin JM; Déruaz-Luyet A; Brodovicz KG; Santiago Ortiz AJ; Bessette LG; Kulldorff M; Schneeweiss S
Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00103. PubMed ID: 31922030
[TBL] [Abstract][Full Text] [Related]
22. Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
Evans M; Husain M; Srivastava A; Mangla KK; Kuhlman AB; Lingvay I
Adv Ther; 2024 May; 41(5):1843-1859. PubMed ID: 38340253
[TBL] [Abstract][Full Text] [Related]
23. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: scandinavian cohort study.
Engström A; Söderling J; Hviid A; Eliasson B; Gudbjörnsdottir S; Wintzell V; Hveem K; Jonasson C; Melbye M; Pasternak B; Ueda P
Eur Heart J Cardiovasc Pharmacother; 2024 Jun; ():. PubMed ID: 38918063
[TBL] [Abstract][Full Text] [Related]
24. SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors.
Tan GSQ; Morton JI; Wood S; Shaw JE; Magliano DJ; Ilomäki J
Clin Pharmacol Ther; 2024 Jun; 115(6):1304-1315. PubMed ID: 38333984
[TBL] [Abstract][Full Text] [Related]
25. Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study.
Tse G; Lee S; Liu T; Zhou J
Cardiovasc Drugs Ther; 2024 Apr; 38(2):391-392. PubMed ID: 38244149
[No Abstract] [Full Text] [Related]
26. New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.
von Lewinski D; Kolesnik E; Wallner M; Resl M; Sourij H
Biomed Res Int; 2017; 2017():1253425. PubMed ID: 28894748
[TBL] [Abstract][Full Text] [Related]
27. The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.
Bittle PA
Nurse Pract; 2017 Jun; 42(6):31-38. PubMed ID: 28225432
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin Transporter and Dipeptidyl Peptidase-4 as New Pharmacological Targets in the Prevention of Acute Kidney Injury in Diabetes: An In Vitro Study.
Gallego-Tamayo B; Santos-Aparicio Á; Yago-Ibáñez J; Muñoz-Moreno L; Lucio-Cazaña FJ; Fernández-Martínez AB
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542317
[TBL] [Abstract][Full Text] [Related]
29. Retracted: Effect of dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled trials.
Shi H; Peng M; Liu Y; Kan Z; Li W; Yang T
Int J Clin Pract; 2021 Dec; 75(12):e14213. PubMed ID: 33819377
[TBL] [Abstract][Full Text] [Related]
30. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.
Htoo PT; NajafZadeh M; Tesfaye H; Schneeweiss S; Wexler DJ; Glynn RJ; Schmedt N; Déruaz-Luyet A; Koeneman L; Paik JM; Patorno E
Diabetes Care; 2024 Jun; ():. PubMed ID: 38917305
[TBL] [Abstract][Full Text] [Related]
31. SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke.
Broome DT
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1450-e1451. PubMed ID: 37061813
[No Abstract] [Full Text] [Related]
32. Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.
Luijken K; van Eekelen R; Gardarsdottir H; Groenwold RHH; van Geloven N
Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):863-872. PubMed ID: 36946319
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Outcomes with Empagliflozin - News for Type 2 Diabetes Therapy.
Gallwitz B
Eur Endocrinol; 2016 Mar; 12(1):31-32. PubMed ID: 29632584
[TBL] [Abstract][Full Text] [Related]
34. A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors.
Khalse M; Bhargava A
Indian J Endocrinol Metab; 2018; 22(5):689-695. PubMed ID: 30294582
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety profile of currently available diabetic drugs.
Azimova K; San Juan Z; Mukherjee D
Ochsner J; 2014; 14(4):616-32. PubMed ID: 25598727
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Chronic Inflammatory Skin Diseases in Type 2 Diabetes Mellitus in Taiwan: A Nationwide Population-Based Cohort Study.
Chiu HY; Lin YJ; Huang YH
J Invest Dermatol; 2024 Mar; ():. PubMed ID: 38537930
[No Abstract] [Full Text] [Related]
37. Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
Cardiovasc Diabetol; 2024 Mar; 23(1):103. PubMed ID: 38500096
[No Abstract] [Full Text] [Related]
38. A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes.
P T; 2010 Feb; 35(2):2-4. PubMed ID: 20221324
[No Abstract] [Full Text] [Related]
39. Much More Than Just Diabetes: The Pivotal Role of Dipeptidyl-Peptidase 4 in Skin Fibrosis.
Vorstandlechner V; Mildner M
J Invest Dermatol; 2024 Jun; ():. PubMed ID: 38842990
[No Abstract] [Full Text] [Related]
40. Is it Time for Trials on Preventing Immune-Mediated Myocardial Damage?
Peyster EG; Margulies KB
JACC Basic Transl Sci; 2021 Jun; 6(6):543-545. PubMed ID: 34222725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
